Main > INFLUENZA VIRUS > Infection. Treatment > Rimantadine

Product USA. D

CLASSIFICATION CommPat. Market
MARKETER'S COUNTRY USA. Available since 1993
OBSERVATION'S Limitations
- Restrict action spectrum
- Rapid viral resistance development
PATENT ASSIGNEE'S COUNTRY USA
SIDE EFFECT'S Adverse reactions in
- CNS
- GI tract
STATUS Patent Expired
THERAPEUTIC CLASS Antiviral (Influenza A)
UPDATE 08.00
PATENT ASSIGNEE This data is not available for free
PATENT PHOTOCOPY Available on request

Want more information ?
Interested in the hidden information ?
Click here and do your request.


back